BIOXYTRAN, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOXYTRAN, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $191.1K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $246.5K | Apr 2, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $246.5K | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $255.8K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $275.6K | Sep 20, 2016 |
| FY2014 | Dec 31, 2013 | $417.3K | Apr 10, 2015 |
| FY2013 | Dec 31, 2012 | $312.9K | Apr 14, 2014 |
| FY2012 | Dec 31, 2011 | $76.3K | Apr 15, 2013 |
| FY2011 | Dec 31, 2010 | $16.1K | Dec 31, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $87.1K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $150.2K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $120.1K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $109.6K | Sep 20, 2016 |
| FY2014 | Dec 31, 2013 | $219.9K | Apr 10, 2015 |
| FY2013 | Dec 31, 2012 | $191.0K | Apr 14, 2014 |
| FY2012 | Dec 31, 2011 | $57.2K | Apr 15, 2013 |
| FY2011 | Dec 31, 2010 | $12.1K | Dec 31, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.12M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.37M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($4.47M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($2.47M) | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | ($4.03M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.54M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.86M) | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | ($296.4K) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($86.4K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($696.8K) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.84M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.22M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.80M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($2.44M) | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | ($4.21M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.27M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($1.63M) | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | ($215.1K) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($86.4K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($671.3K) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $454.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $112.3K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.15M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.28M | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | $2.01M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $544.5K | Apr 11, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $397.7K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $821.5K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $2.21M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.39M | Sep 20, 2016 |
| FY2014 | Dec 31, 2013 | $2.19M | Apr 10, 2015 |
| FY2013 | Dec 31, 2012 | $2.48M | Apr 14, 2014 |
| FY2012 | Dec 31, 2011 | $4.49M | Apr 15, 2013 |
| FY2011 | Dec 31, 2010 | $341.1K | Dec 31, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($526.5K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($381.3K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($775.4K) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($1.80M) | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | ($1.70M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.10M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($431.0K) | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | ($185.9K) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $110 | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($42.4K) | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $658.6K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $138.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $139.4K | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $370.9K | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | $119.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $326.4K | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $219.6K | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $36.4K | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $110 | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $51.7K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.25M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.93M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $3.24M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $3.67M | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | $3.28M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.27M | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.02M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $261.7K | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | $1.4K | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $342.3K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | ($3.16M) | Apr 11, 2022 |
| FY2021 | Dec 31, 2020 | ($1.94M) | Apr 11, 2022 |
| FY2021 | Dec 31, 2019 | ($799.3K) | Apr 11, 2022 |
| FY2020 | Dec 31, 2018 | ($225.3K) | Apr 9, 2021 |
| FY2018 | Dec 31, 2017 | ($1.3K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($290.6K) | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | ($195.2K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | ($221.5K) | Mar 31, 2017 |
| FY2016 | Dec 31, 2013 | $75.4K | Mar 31, 2017 |
| FY2014 | Dec 31, 2012 | $354.1K | Apr 10, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.04M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($18.92M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($15.70M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($11.23M) | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | ($8.75M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.72M) | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | ($2.24M) | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | ($382.8K) | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | ($86.4K) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($13.88M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $11.1K | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $3.5K | Mar 31, 2017 |
| FY2016 | Dec 31, 2014 | $6.2K | Mar 31, 2017 |
| FY2016 | Dec 31, 2013 | $20.7K | Mar 31, 2017 |
| FY2014 | Dec 31, 2012 | $5.5K | Apr 10, 2015 |
| FY2013 | Dec 31, 2011 | $16.5K | Apr 14, 2014 |
| FY2012 | Dec 31, 2010 | $22.8K | Apr 15, 2013 |
| FY2011 | Dec 31, 2009 | $5.7K | Dec 31, 2012 |
| FY2011 | Jun 8, 2008 | $0 | Mar 16, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jan 13, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 108.15M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 86.78M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 144.64M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 123.35M | Jan 13, 2025 |
| FY2022 | Dec 31, 2021 | 110.84M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 97.45M | Apr 11, 2022 |
| FY2020 | Dec 31, 2019 | 86.48M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | 85.10M | Mar 18, 2020 |
| FY2018 | Dec 31, 2017 | 85.10M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 28.17M | Apr 2, 2018 |